Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Retained Earnings (2020 - 2025)

Tarsus Pharmaceuticals has reported Retained Earnings over the past 6 years, most recently at $381000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $381000.0 for Q4 2025, up 112.85% from a year ago — trailing twelve months through Dec 2025 was $381000.0 (up 112.85% YoY), and the annual figure for FY2025 was $381000.0, up 112.85%.
  • Retained Earnings for Q4 2025 was $381000.0 at Tarsus Pharmaceuticals, up from $289000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for TARS hit a ceiling of $381000.0 in Q4 2025 and a floor of -$405.7 million in Q2 2025.
  • Median Retained Earnings over the past 5 years was -$27.2 million (2021), compared with a mean of -$91.6 million.
  • Biggest five-year swings in Retained Earnings: crashed 4213612.5% in 2024 and later surged 112.85% in 2025.
  • Tarsus Pharmaceuticals' Retained Earnings stood at -$46.7 million in 2021, then plummeted by 133.04% to -$108.8 million in 2022, then tumbled by 124.94% to -$244.7 million in 2023, then surged by 100.07% to $179000.0 in 2024, then soared by 112.85% to $381000.0 in 2025.
  • The last three reported values for Retained Earnings were $381000.0 (Q4 2025), $289000.0 (Q3 2025), and -$405.7 million (Q2 2025) per Business Quant data.